LCA Gene Therapy in Somatic Cell-Derived Induced Pluripotent Stem Cells

体细胞衍生的诱导多能干细胞中的 LCA 基因治疗

• 批准号: 8580180
• 负责人: ERIN R BURNIGHT
• 金额: $ 5.63万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-12-01 至 2015-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8580180
• 关键词: Affect; Animal Model; Automobile Driving; Biological Assay; Biopsy; Blindness; Candidate Disease Gene; Cells; Child; Clinical Trials; Degenerative Disorder; Dependovirus; Dermal; Disease; Disease Progression; Disease model; Dissection; Effectiveness; Eye; Fibroblasts; Gene Proteins; Gene Transfer; Generations; Genes; Human; In Vitro; Inherited; Leber' s amaurosis; Lentivirus Vector; Life; Mediating; Modeling; Mus; Mutant Strains Mice; Mutation; Neural Retina; Nuclear; Pathologic Nystagmus; Patients; Phase; Photoreceptors; RPE65 protein; Replacement Therapy; Research; Research Personnel; Retina; Retinal; Retinal Degeneration; Skin; Somatic Cell; Stargardt' s disease; Stem cells; Structure; Structure of retinal pigment epithelium; Study models; Subfamily lentivirinae; System; Technology; Teratoma; Testing; Therapeutic; Therapy Clinical Trials; Thick; Tissues; Transplantation; Viral Vector; Virus Diseases; base; cell type; gene correction; gene replacement; gene replacement therapy; gene therapy; gene transfer vector; human disease; human subject; in vivo; induced pluripotent stem cell; mouse model; pre-clinical; precursor cell; promoter; public health relevance; regenerative; regenerative therapy; retinal progenitor cell; stem cell technology; stem cell therapy; subretinal injection; success; therapeutic gene; transcription factor; vector; vector-induced

DESCRIPTION (provided by applicant): Leber Congenital Amaurosis (LCA) is the most severe form of inherited retinal degenerative diseases and is characterized by early on-set nystagmus and blindness, generally occurring within the first year of life. 21% of LCA patients carry mutations in the CEP290 gene, implicating it as a major contributor to the disease. Moreover, CEP290-associated LCA is inherited in an autosomal recessive manner, making it a good candidate for gene-replacement therapy. The recent success of a phase I gene therapy trial for LCA also highlights this treatment as a feasible option for LCA patients. Although this disease may be treatable by gene-replacement therapy using viral vectors, the size of CEP290 precludes the current vector system (adeno-associated virus - AAV) from efficiently packaging the gene. An alternative to AAV for ocular gene transfer is lentivirus. The packaging limit is much greater than that of AAV, and thus will accommodate the large CEP290 gene. Moreover, lentiviral vectors can transduce multiple cell types in the eye, including photoreceptors and retinal pigment epithelium - cell types important in the disease progression of LCA. Pre-clinical animal models of LCA will be useful for studying the effectiveness of CEP290-replacement therapy. The CEP290rd16 mouse model carries a homozygous in-frame 897 bp deletion in the Cep290 gene. These mice display early progressive degeneration of the outer segment and reduction in thickness of the outer nuclear layer, which resembles the human disease. In addition to the CEP290rd16 mouse model, generation of tissue specific retinal cell types from patients with CEP290-associated LCA will make a good model for studying the effectiveness of CEP290-replacement therapy. New induced pluripotent stem cell (iPSC)-based technologies are providing researchers with the ability to model and study human disease and therapeutic correction. In this proposal we aim to generate iPSCs and subsequently photoreceptor precursor cells from a mouse model of retinal degeneration as well as patients with CEP290-associated LCA retinal degenerative disorder. These cells will be used both in and ex vivo for the study of therapeutic gene correction using lentiviral vectors and induced pluripotent stem cell technology.

描述（由申请人提供）：Leber先天性黑蒙（LCA）是遗传性视网膜变性疾病中最严重的一种，其特征是早期发作的眼球震颤和失明，通常发生在生命的第一年内。21%的LCA患者携带CEP 290基因突变，这意味着它是该疾病的主要贡献者。此外，CEP 290相关LCA以常染色体隐性方式遗传，使其成为基因替代疗法的良好候选者。最近一项针对LCA的I期基因治疗试验的成功也突出了这种治疗作为LCA患者的可行选择。虽然这种疾病可以通过使用病毒载体的基因替代疗法来治疗，但CEP 290的大小排除了当前载体系统（腺相关病毒- AAV）有效地包装基因。用于眼部基因转移的AAV的替代物是慢病毒。包装极限比AAV大得多，因此将容纳大的CEP 290基因。此外，慢病毒载体可以感染眼睛中的多种细胞类型，包括光感受器和视网膜色素上皮细胞-在LCA疾病进展中重要的细胞类型。LCA的临床前动物模型将有助于研究CEP 290替代疗法的有效性。CEP 290 rd 16小鼠模型在Cep 290基因中携带纯合的框内897 bp缺失。这些小鼠表现出早期进行性外节变性和外核层厚度减少，这类似于人类疾病。除了CEP 290 rd 16小鼠模型之外，从患有CEP 290相关LCA的患者中产生组织特异性视网膜细胞类型将成为研究CEP 290替代疗法的有效性的良好模型。新的基于诱导多能干细胞（iPSC）的技术为研究人员提供了建模和研究人类疾病和治疗校正的能力。在这项提案中，我们的目标是从视网膜变性的小鼠模型以及患有CEP 290相关LCA视网膜变性疾病的患者中产生iPSC和随后的感光细胞前体细胞。这些细胞将在体内和体外用于使用慢病毒载体和诱导多能干细胞技术进行治疗性基因校正的研究。